Selected stock price target news of the day - April 7th, 2025

By: Matthew Otto

Anavex Reports 192-Week Blarcamesine Benefits in Early Alzheimer’s

Anavex Life Sciences reported results from the ATTENTION-AD trial of blarcamesine (ANAVEX®2-73), with data presented at the AD/PDTM 2025 Conference. The study followed 325 participants with early Alzheimer’s disease for up to 192 weeks.

Early-start patients (about 163 participants) showed an improvement in both cognitive function and daily activities compared to late-start patients (about 162 participants). Specifically, the early treatment group experienced a 3.83-point improvement on the ADAS-Cog13 memory test (which ranges from 0 to 70, with higher scores indicating worse cognitive decline) and a 4.30-point improvement on the ADCS-ADL daily functioning scale (which ranges from 0 to 78, with higher scores indicating better functioning). Patients who received uninterrupted treatment saw even greater benefits, with a 4.20-point improvement on the ADAS-Cog13 and a 5.75-point improvement on the ADCS-ADL at Week 192.

The trial included participants from Canada, Europe (96-week open-label extension), and Australia (144-week extension). Currently, 74 individuals continue to receive daily oral blarcamesine under a Compassionate Use Program, with some treated for over 9 years without serious adverse effects.

Alzheimer’s disease affects over 32 million people globally and more than 6.7 million in the U.S. alone, with early-stage patients estimated to represent 40–50% of that population. This means over 13 million people worldwide—and approximately 3 million in the U.S.. The most common adverse event, dizziness, declined from 25.2% in earlier trials to 9.6% after adjusting the titration period to 10 weeks.

Analysts Maintain Bullish Outlook Following Blarcamesine Data

D. Boral Capital analyst Jason Kolbert maintained a Buy rating and a $46 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating and a $42 price target.

Which Analyst has the best track record to show on AVXL?

Analyst Raghuram Selvaraju (HC WAINWRIGHT) currently has the highest performing score on AVXL with 4/14 (28.57%) price target fulfillment ratio. His price targets carry an average of $33.42 (389.51%) potential upside. Anavex Life Sciences stock price reaches these price targets on average within 155 days.

Tesla Faces Strategic Pressure as CATL Advances Battery Swapping Network Through Nio Power Deal

Tesla may face rising competitive pressure in China as CATL moves to acquire a controlling stake in Nio Power—an infrastructure unit that operates over 3,200 battery swapping stations across the country. </span>

style=”font-weight: 400;”>The proposed deal follows CATL’s March announcement of approximately $342 million USD investment in Nio Power, which was valued at over about $1.37 billion USD during a 2024 fundraising round. While Tesla currently relies exclusively on its proprietary Supercharger network and has not adopted battery swapping, Nio Power provides fast-swap battery solutions not only for Nio vehicles but also for other EV brands, including Tesla and BYD.</span>

CATL recently partnered with state-owned Sinopec to build 10,000 battery swapping stations across China, with at least 500 slated for completion in 2025. Nio Power’s network already enables drivers to replace depleted batteries in under three minutes, a convenience that may appeal to EV users wary of long charging times.</span>

Analyst Ratings Reflect Caution Amid Infrastructure Shifts in China

Wedbush analyst Daniel Ives maintained an Outperform rating but lowered the price target from $550 to $315.
Cantor Fitzgerald’s Andres Sheppard reiterated an Overweight rating.

Which Analyst has the best track record to show on TSLA?

Analyst Andres Sheppard (CANTOR FITZGERALD) currently has the highest performing score on TSLA with 19/21 (90.48%) price target fulfillment ratio. His price targets carry an average of $157.72 (59.01%) potential upside. Tesla stock price reaches these price targets on average within 21 days.

Microsoft to Cease Operations of Wicresoft in China, Leading to 2,000 Layoffs

Microsoft’s joint venture, Wicresoft, will cease operations in China starting Tuesday, resulting in the layoff of approximately 2,000 employees, according to a report by Chinese media outlet Caijing. The decision is in line with Microsoft’s broader strategy to discontinue outsourcing after-sales support in China to Wicresoft.

This move has raised concerns about how Microsoft will continue to support its China-based users of products such as Windows and Office. Wicresoft, which was founded in 2002, has had a presence in China with a workforce of 2,000 employees dedicated to supporting Microsoft’s services in the region.</span>

The shutdown of Wicresoft’s China operations marks a retreat by Microsoft from the Chinese market amidst growing political and trade tensions between the U.S. and China. Additionally, it faces intense competition from local players like Kingsoft. Earlier this year, Microsoft also closed a Shanghai lab focused on IoT and AI technologies. With over 10,000 employees globally, Wicresoft also operates in the U.S., Europe, and Japan.

Analyst Maintains Rating, Lowers Price Target Amid Shutdown

Jefferies analyst Brent Thill maintained a Buy rating but lowered the price target from $500 to $475.

Which Analyst has the best track record to show on MSFT?

Analyst Mark Murphy (JPMORGAN) currently has the highest performing score on MSFT with 26/28 (92.86%) price target fulfillment ratio. His price targets carry an average of $60.27 (14.89%) potential upside. Microsoft stock price reaches these price targets on average within 117 days.